$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞格非尼(瑞戈非尼)治疗肝癌的疗效
2025-10-19 11:44:20
Check Details
肝癌靶向药物乐伐替尼与索拉非尼临床数据
2025-10-19 11:44:20
Check Details
瑞戈非尼治疗多吉美耐药的肝癌患者
2025-10-19 11:44:20
Check Details
卡博替尼为多吉美治疗失败肝癌患者提高了新选择
2025-10-19 11:44:20
Check Details
瑞格非尼改善索拉非尼耐药患者生存期
2025-10-19 11:44:20
Check Details
肝癌治疗药物-乐伐替尼
2025-10-19 11:44:20
Check Details
乐伐替尼一线治疗肝癌疗效
2025-10-19 11:44:20
Check Details
卡博替尼治疗晚期肝癌疗效优于安慰剂
2025-10-19 11:44:20
Check Details
乐伐替尼一线治疗肝癌的总体效果
2025-10-19 11:44:20
Check Details
索拉非尼治疗肝癌临床数据
2025-10-19 11:44:20
Check Details
卡博替尼可减轻56%肝癌进展风险
2025-10-19 11:44:20
Check Details
索拉非尼治疗晚期肝癌患者的疗效
2025-10-19 11:44:20
Check Details
1
2
...
2567
2568
2569
2570
2571
2572
2573
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
2
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
3
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
4
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
5
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
6
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
7
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
8
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
9
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
10
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
11
Vemurafenib (Zelboraf) Complete Medication Guide
12
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice